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Somatostatin is a tetradecapeptide hormone first identified in the
hypothalamus as an inhibitor of growth hormone (GH) release. The
peptide has subsequently been found throughout the body, particu-
larly in the pancreas, gastrointestinal tract and nervous system. As
well as inhibiting hormone release, somatostatin functions as a
neurotransmitter, immunomodulator and suppressor of angiogenesis
and cell proliferation (Reichlin, 1983a,b; Schally, 1988; Patel et al,
1994; Pollak and Schally, 1998). Somatostatin acts by binding to
specific receptors (sst) of which five principal subtypes have been
identified: sst1, sst2, sst3, sst4 and sst5 (Bruns et al, 1994).
RC-160 (D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2) is a
potent cyclic octapeptide analogue of somatostatin (Cai et al,
1986). RC-160 is up to 500 times more potent than octreotide and
somatuline in inhibiting the synthesis/release of hormones from sst
expressing pituitary and malignant neuroendocrine cells, although
the maximal inhibitory effects are similar (Hofland et al, 1994).
RC-160 inhibits the growth of sst positive colonic, pancreatic,
gastric, lung and both androgen-dependent and -independent
prostatic cancer and glioblastoma and osteosarcoma tumours
(Schally, 1988; Qin et al, 1995; Pinski et al, 1996; Pollak and
Schally, 1998). In transfection experiments, sst2 and sst5 have
been shown to be the principal receptor subtypes involved in
mediating the growth inhibitory effects of RC-160 (Buscail et al,
1994, 1995; Cordelier et al, 1997). RC-160 activates phosphotyro-
sine phosphatases (PTPs), which dephosphorylate tyrosine
residues of activated type 1 growth factor receptors, including
epidermal growth factor, and inhibits intracellular cAMP and
cGMP accumulation and calcium mobilization (Schally, 1988;
Buscail et al, 1994; Buscail et al, 1995; Qin et al, 1995; Cordelier
et al, 1997; Pollak and Schally, 1998). The growth inhibitory
effects of RC-160 in sst positive cancer cell lines have been
directly linked to activation of PTPs and inhibition of intracellular
cAMP production in vitro (Liebow et al, 1988; Qin et al, 1995).
Somatostatin analogues also inhibit the growth of sst negative
tumours in in vivo studies, suggesting important indirect anti-
proliferative effects. Many tumours express insulin-like growth
factor-I (IGF-I) receptors and proliferate in response to exposure
to IGF-I (Macaulay, 1992). Through down-regulation of the
growth hormone GH/IGF-I axis, somatostatin analogues may
inhibit the growth of IGF-I responsive tumours (Holly, 1998;
Pollak and Schally, 1998). The growth inhibitory effects of 
RC-160 in sst negative tumours are associated with a decrease in
serum growth hormone (GH) and IGF-I levels and in tumour IGF-
I receptor expression (Pinski et al, 1994, 1996). Somatostatin
analogues are also potent anti-angiogenic agents, having direct
growth inhibitory effects on proliferating endothelial cells (Patel et
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UKal, 1994). As angiogenesis is essential for tumour growth beyond
1–2 mm in diameter, inhibition of this process may result in
tumour growth inhibition (Folkman, 1995).
In the region of between 70 and 90% of breast tumours express
specific high affinity binding sites for radiolabelled somatostatin
analogues (Prevost and Israel, 1993, Van Eijck et al, 1994). The
principal subtype detected is sst2 (Evans et al, 1997). The octapep-
tide somatostatin analogues, including RC-160, inhibit the growth
of sst expressing breast tumours in vitro and in vivo (Setyano-Han
et al, 1987; Szende et al, 1989; Szende et al, 1991; Brower et al,
1992; Szepeshazi et al, 1992; Prevost and Israel, 1993). The
regressive changes in vivo are consistent with apoptosis and coag-
ulation necrosis (Szende et al, 1989, 1991). IGF-I is a potent
mitogen for breast cancer cells. The growth effects are mediated
through high affinity IGF-I receptors, which have been found to be
expressed by the majority of breast tumours (Klijn et al, 1993;
Helle and Lonning, 1996). RC-160 therapy results in down-regula-
tion of IGF-I receptor expression in MXT mouse mammary carci-
noma (Srkalovic et al, 1989). Therefore, RC-160 therapy may
inhibit breast cancer growth through modulation of the mitogenic
effects of IGF-I.
A number of small studies have evaluated somatostatin
analogues in the management of breast cancer. Treatment rarely
induces an objective response, although disease stabilization has
been reported in 20–43% of cases. When studied, only a moderate
and non-durable reduction in IGF-I levels was seen (Manni et al,
1989; Morere et al, 1989; Vennin et al, 1989; Stolfi et al, 1989;
Prevost and Israel, 1993; Di Leo et al, 1995; Ingle et al, 1996).
Toxicity in all studies was mild, transient diarrhoea being the most
common observed problem. Other side-effects of somatostatin
analogue therapy include pain at the injection site, glucose intoler-
ance and gallstone formation (Battershill and Clissold, 1989).
The work presented evaluated single agent, high-dose, contin-
uous infusional RC-160 in the management of patients with
pretreated metastatic breast cancer.
PATIENTS AND METHODS
Entry criteria
In a phase II single-centre study we evaluated the efficacy of RC-
160 (Debiopharm SA, Lausanne, Switzerland) in the management
of patients with relapsed breast cancer following previous
systemic therapy. Inclusion criteria included cytologically and/or
histologically proven breast cancer, at least unidimensionally
measurable disease, age ³ 18 years, life expectancy ³ 3 months,
performance status ≤ 2, haemoglobin ³ 10 g dl–1, white cell count
³ 3 ´ 109 l–1, absolute neutrophil count ³ 2 ´ 109 l–1, platelets
³ 100 ´ 109 l–1, bilirubin ≤ 2 ´ normal (N), aspartate and alanine
transferase ≤ 3 ´ N unless due to metastases where values ≤ 5 ´ N
were accepted and plasma creatinine ≤ 150 mmol L–1. Patients who
had received intensive chemotherapy or radiotherapy within the
previous 3 weeks, pregnant women or, where appropriate, those
not taking adequate contraceptive precautions were excluded from
the study.
Pretreatment evaluation included a minimum of a history and
physical examination, a full blood count (FBC), renal, liver and
bone biochemistry, fasting blood sugar, a chest X-ray and ultra-
sound examination of the abdomen. Response was assessed
according to standard WHO criteria. All evaluable/measurable
sites of disease were recorded prior to commencing therapy
employing further radiological techniques as deemed necessary.
Clinical photographs and measurements of skin lesions and/or
lymph nodes were also performed and utilized for response assess-
ment where appropriate.
The RC-160 was supplied as a lyophilized powder in sterile
vials. The powder was dissolved in sterile water for injection. The
powder contained a glutamate excipient and the reconstituted solu-
tion had a pH = 4.5 (Debiopharm SA). The reconstituted solution
was administered by continuous subcutaneous infusion using a
Walkmed 350 pump (Medex Medical Inc., Rossendale, UK).
Continuous infusion was chosen to facilitate the administration of
high-dose RC-160, to maintain relatively steady-state RC-160
plasma levels (not formally tested) and because RC-160 is being
developed as a slow release formulation for depot injection
(unpublished data), as have the other principal somatostatin
analogues octreotide and somatuline (Caron et al, 1997; Helle et
al, 1998). Initially, either a 23G Butterfly needle (Venisystems,
Sligo, Ireland) or a 22G Intima catheter (Becton Dickinson, Sandy,
Utah, USA) was implanted into the anterior abdominal wall, alter-
nating between the two types for each patient to investigate the
efficacy and side-effects of each. The RC-160 infusion was started
at 3 mg day–1 increasing after 1 week to 4.5 mg day–1 and after 4
weeks to 6 mg day–1. Patients were treated on an in-patient basis
for the first 2 days of therapy in order to become familiar with the
pumps and to report any untoward side-effects. No problems were
observed with RC-160 solubility in preclinical testing, at the time
of preparation of the solution or during treatment.
Planned follow-up assessments included an FBC, biochemistry
profile and fasting blood sugar, IGF-1 and PRL levels on days 7,
28 and monthly thereafter. Measurable sites of disease were to be
evaluated after 28 days and subsequently every 2 months. The
study was approved by the local Ethics Committee and patients
were included only after giving informed written consent.
Serum insulin-like growth factor I and prolactin levels
IGF-I and PRL levels were evaluated in fasting serum samples
obtained prior to commencing RC-160 treatment, and after 1, 4
and every 4 weeks thereafter until treatment was discontinued.
IGF-I levels were measured using the Octeia IGF-I kit, a two
site immunoenzymometric assay (IEMA) (Immunodiagnostic
Systems Ltd., Boldon, Tyne and Wear, UK). The sensitivity of the
assay is < 1 nmol l–1. The intra-assay coefficient of variance is
2.3–3.5% and the interassay variance is 6.95–7.14%. The normal
ranges are 9.5–45 nmol l–1 for women aged 21–40 years, 7.5–
30 nmol l–1 for women aged 41–60 years and 5–22.5 nmol l–1 for
women aged > 60 years. PRL levels were measured using AxSYM
prolactin, a microparticle enzyme immunoassay (MEIA) (Abbott
Laboratories, Diagnostics Division, Abbott Park, IL 60064, USA).
The sensitivity of the assay is 15 mU/l–1. The intra-assay coeffi-
cient of variance is 2.81–4.13% and the interassay variance is
0–4.97%. The normal range is 33–580 mU/l–1.
Statistical methods
The paired Student’s t test was used to determine the equality of
paired means for glucose, IGF-I and PRL levels on treatment. The
analysis was performed employing the Stata statistical software,
release 5.0 package (Stata, College Station, TX, USA).
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Fourteen women, age range 37–80 years (median 58.5 years),
ECOG performance status 0–2, with stage IV breast cancer were
recruited to the study. Patient characteristics are summarized in
Table 1. All patients had received prior radiotherapy and endocrine
agents and/or cytotoxic chemotherapy on at least one occasion,
either in the adjuvant setting or for advanced disease.
Toxicity
Toxicities are summarized in Table 2. No grade 3 or 4 toxicities
were seen. Haematological toxicities were virtually absent, while
no alterations were seen in renal or liver function. A significant
increase was seen in fasting blood glucose levels, the mean rising
from 5.3 mmol l–1 to 6.2 mmol l–1 (P = 0.0012). The most common
side-effects included mild fatigue and diarrhoea. The diarrhoea
was associated with steatorrhoea in five cases. Two patients
reported a marked increase in borborygmi. Regular anti-emetics
were required for mild nausea by seven patients. Both patients
with liver metastases experienced nausea which, although present
at baseline, worsened on treatment
The most troublesome side-effect was inflammation at the infu-
sion site seen in 11 patients associated with the development of
subcutaneous abscesses in eight. Two cases were lanced. These
and two others were treated with oral antibiotics. In two cases
swab cultures grew Staphlococcus aureas. However, it became
apparent with time that the abscesses probably represented local
reactions either to the cannulas or to the RC-160 infusion itself.
This led to a policy of resiting the cannula site weekly, whether or
not there was a problem. Subsequently, abscess formation became
less of a problem without the need for therapeutic intervention.
Regarding the assessment of cannula type, the Intima cannula
proved more user friendly than Butterfly needles, being subjec-
tively more comfortable for the patient and easier to secure.
Serum IGF-I and PRL levels
IGF-I levels fell in all patients treated with RC-160. The mean level
for the 14 patients decreased by 45% by day 7 (P < 0.0001). No
subsequent significant change was seen between days 7, 28 and 56,
despite increasing doses of the medication (Figure 1). Only three
patients were sampled on day 84. Again the values were similar to
those on day 7. Samples were obtained from two patients off treat-
ment and doubled from the last on treatment sample. PRL levels
were within the normal range in 11 of the 14 patients evaluated and
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Table 1 Clinical characteristics of patients (pts)
Fourteen women recruited to study
Age: median 61.3 years
range 37–80 years
ECOG performance status 0–2 (median 1)
Histological subtypes
Invasive ductal 10 pts
Lobular 2 pts
Mixed ductal and lobular 1 pt
Other 1 pt
Previous treatments
Prior endocrine therapy 13 pts
adjuvant 6 pts
advanced 10 pts
Prior chemotherapy 12 pts
adjuvant 7 pts
advanced 10 pts
Prior radiotherapy
local 14 pts
ablative oophorectomy 1 pts
metastatic 3 pts
Sites of disease
Skin 8 pts
Lymph nodes 6 pts
Bone 5 pts
Pleura 5 pts
Soft tissue 3 pts
Lung 3 pts
Liver 2 pts
Breast 2 pts
Adrenal 1 pt
Table 2 Number of patients developing grade 1 and 2 toxicities based on
CALGB common toxicity criteria (total number of patients in study = 14)
Grade
Toxicity 1 2
Diarrhoea 9 3
Vomiting 4 1
Nausea 4 3
Fatigue 7 5
Headache 6 1
Constipation 2 1
Abdominal pain 3 2
Inflammation at infusion site 7 4
No grade 3 or 4 toxicities were seen in any of the patients. Four patients with
inflammation at the infusion site were treated with antibiotics until we
determined that the problem was due to sterile abscess formation.
Borborygmi were recorded in two patients and steatorrhoea in five.
Haematological toxicities were rare with two patients developing grade 1
neutropenia and one a grade 2 leucopenia.
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Figure 1 Serum IGF-1 (mean±SE). Paired test: pre vs. day 7, P < 0.00001
(n = 14); pre vs. day 28, P < 0.0002 (n = 11); pre vs. day 56, P < 0.0009
(n = 8); day 7 vs. day 28, P = NS (n = 11); day 28 vs. day 56, P = NS (n =8 )were not affected by RC-160 therapy. However, elevated levels
seen in three patients fell to normal within 7 days of commencing
the RC-160 infusion (Figure 2).
Response
No objective tumour responses were seen, all patients showing
objective evidence of progressive disease within 3 months of
commencing RC-160 treatment.
DISCUSSION
Breast cancer is the most prevalent malignant disease among
women in developed countries. When the disease has spread
beyond the breast and axilla, it is essentially incurable and therapy
is palliative, being directed at prolonging survival and improving
symptom control (Hayes et al, 1995; Goldhirsch and Gelber,
1996). Somatostatin analogues are among the novel hormonal
agents being investigated for the treatment of breast cancer.
Although RC-160 represents the most potent of the principal
somatostatin analogues in clinical development and is well toler-
ated when administered in high dose as a continuous subcutaneous
infusion, the agent proved to be ineffective in the treatment of
relapsed, previously treated, metastatic breast cancer. This is in
keeping with the results reported for the somatostatin analogues,
octreotide and somatuline (Manni et al, 1989; Morere et al, 1989;
Stolfi et al, 1989; Vennin et al, 1989; Prevost and Israel, 1993;
Di Leo et al, 1995; Ingle et al, 1996). Similar results are also seen
in inoperable pancreatic cancer where, although tumour growth
was stabilized and symptoms improved in a proportion of patients,
it was felt that RC-160 alone, even in large doses, is insufficient
to produce effective palliation in these patients (Poston and
Schally, 1993).
One of the principal side-effects seen was the development of
skin inflammation in 11 patients, associated with cutaneous
abscesses at the cannulation site in eight. These were initially
treated as being infected. However, with experience the suspicion
increased that the abscesses were most probably sterile and repre-
sented a reaction to either the cannula or to the infusion itself.
Similar findings have been documented in patients treated at other
centres with infusional RC-160. In a number of cases the material
from the abscesses has been studied microscopically, revealing
florid chronic inflammation with infiltration by multinucleated
giant cells. In a study in the Yucatan minipig, prolonged sub-
cutaneous catheter implantation induced focal ulceration in the
epidermis in one of six animals, fibroblast proliferation in the
dermis and local inflammation centred around the catheter.
Vapreotide with or without glutamate excipient at a concentration
of 1.5 mg ml–1 induced granulomas surrounded with fibrosis, asso-
ciated sometimes with local oedema (Debiopharm SA; unpub-
lished data). This led to a policy of resiting the cannula on a
weekly basis, which eased the problem considerably. A small but
significant increase in fasting blood glucose levels, and mild
gastrointestinal side-effects were also seen in keeping with known
side-effects of somatostatin analogue therapy (Battershill and
Clissold, 1989). The only therapeutic intervention required was
the use of anti-emetics in seven patients.
A significant reduction in serum IGF-I levels was seen, levels
falling in all patients as compared with baseline. Unlike previous
studies in breast cancer, where lower doses of octreotide and
somatuline were used, the high dose continuous infusion of RC-
160 induced a 45% reduction in serum IGF-I levels which was
sustained over time (Manni et al, 1989: Vennin et al, 1989; Di Leo
et al, 1995). This is likely to be a result of the dose used as in a
recent phase I study in 14 patients with gastrointestinal tract and
pancreatic cancer, microencapsulated octreotide pamoate 90 mg
i.m. every 4 weeks or 160 mg i.m. every 2 weeks (> 3 mg day–1)
produced an equivalent sustained reduction in plasma IGF-I levels
of 49–53% (Helle et al, 1998).
The lack of efficacy of single agent somatostatin analogue
therapy in breast cancer may in part be due to the antagonistic
effects of oestrogen (Setyano-Han et al, 1987). Recent in vitro and
in vivo studies indicate that anti-oestrogens may potentiate the
anti-tumour activity of somatostatin analogues in breast cancer
(Weckbecker et al, 1994; Candi et al, 1995; Pollak, 1996; Xu et al,
1996). In 33 post-menopausal women with untreated breast cancer
the combination of depot injections of somatuline with oral
tamoxifen resulted in an objective response rate of 50% (95% CI:
35–69%) (Canobbio et al, 1995). The potential therapeutic bene-
fits of combined manipulation of the GH/IGF-I and gonadotropin/
sex steroid axes in sex hormone-associated tumours is supported
by a recent study combining anti-androgen therapy with RC-160
in 19 men with hormone refractory prostate cancer. After 3
months, 14 patients showed a decrease in serum prostate-specific
antigen levels, reduction in bone pain and improvement in
Karnofsky performance status (Gonzalez-Barcena et al, 1998).
Experimental evidence suggests that PRL, a growth factor for
normal breast tissue, is an autocrine factor for breast cancer.
Tumour cells have been demonstrated to express both PRL and
PRL-receptors (Clevenger et al, 1995; Das and Vonderhaar, 1996).
The prolactin receptor, of which three subtypes have been identi-
fied, belongs to the superfamily of cytokine receptors. Binding of
PRL to the PRL-receptor results in activation of cytoplasmic signal
transducers and transcriptional activators through phosphorylation
of JAK2 kinases. Recent work has shown that activation of breast
cancer cell line PRL receptors results in stimulation of the ras-raf-
MEK(MAP kinase kinase)-MAP kinase mitogenic pathway. The
activation of ras is mediated via tyrosine phosphorylation of SHC,
recruitment of GRB2 and the guanine nucleotide exchange factor
SOS (Erwin et al, 1995; Das and Vonderhaar, 1996).
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Figure 2 RC-160 therapy resulted in normalization of serum prolactin in all
3 patients with elevated levels pretreatmentRC-160 reduced serum PRL to within the normal range in all
three patients with elevated levels prior to commencing treatment.
Somatostatin analogues have little or no effect on primary
pituitary hyperprolactinaemia (Lamberts et al, 1991). These find-
ings suggest that the elevated PRL levels seen in the patients in our
study are due to synthesis and release of the peptide from breast
cancer cells. The reduction of elevated PRL levels to within
the normal range and activation of PTPs in tumours expressing
sst2 suggest that RC-160 may counteract the tumour growth
stimulating effects of PRL in some breast cancer patients. A recent
study of triple therapy with tamoxifen, the anti-prolactin agent CV
205–502 and octreotide gave an objective response in five of nine
evaluable patients. A significant reduction in IGF-I levels was seen
similar to that documented in the present study. Furthermore, a
strong significant reduction in circulating PRL levels was docu-
mented in patients with normal PRL secretion (Bontenbal et al,
1998). RC-160 may have a role to play in this setting.
In experimental models octreotide has been shown to enhance
the efficacy of cytotoxic agents in the treatment of solid tumours
while ameliorating their side-effects. The drugs studied include
doxorubicin, paclitaxel, mitomycin C and 5-fluorouracil all of
which are routinely used in the management of metastatic breast
cancer (Lee et al, 1993; Weckbecker et al, 1996). The enhanced
anti-tumour activity may in part be explained by the inhibitory
effects of somatostatin analogues on angiogenesis, as known anti-
angiogenic agents such as TNP-470 and minocycline have been
shown to increase the anti-tumour activity of cyclophosphamide
(Patel et al, 1994; Teicher et al, 1994). In keeping with these find-
ings, RC-160 has been shown to increase the effectiveness of 5-
fluorouracil in vivo (Szepeshazi et al, 1991). These results suggest
the merit of evaluating the combination of somatostatin analogues
with cytotoxic agents in breast cancer therapy, initially in animal
models and subsequently in phase I studies. Cytotoxic analogues
of somatostatin containing potent anthracyclines have recently
been developed and have shown promising anti-tumour activity in
vitro and in vivo in a number of sst positive solid tumours
including breast cancer. The possibility of specifically targeting
sst-rich tumours in patients with such agents is an exciting
prospect for the future (Nagy et al, 1998).
IGF-I is a potent trophic and survival factor for many normal
cells including those of the breast and prostate gland.
Overexpression of growth hormone and IGF-I receptor agonists is
associated with the development of breast cancer in transgenic mice
(Tornell et al, 1992; Bates et al, 1995). In two recently published
prospective studies, high normal IGF-I levels were associated with
an increased relative risk for the development of prostate cancer in
men (4.3) and breast cancer in premenopausal women (7.28 in
premenopausal women aged < 50 years, when adjusted for IGF
binding protein-3 levels) (Chan et al, 1998; Haankinson et al,
1998). Given the sustained suppression of IGF-I levels documented
in the present study, RC-160 alone or in combination with tamox-
ifen or LHRH analogues or antagonists may have a role in the
chemoprevention of breast and prostate cancer (Holly, 1998).
In conclusion, although ineffective as single agent therapy,
high-dose RC-160 is well tolerated, induces a significant and
sustained reduction in serum IGF-1 levels and normalizes hyper-
prolactinaemia in patients with pretreated metastatic breast cancer.
Based on the favourable toxicity profile and the encouraging
preclinical findings, further experimental and clinical studies
combining RC-160 with anti-oestrogens, antiprolactins, cytotoxic
and anti-angiogenic agents are warranted.
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